Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011719 · ClinicalTrials.gov registry record · Phase 3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
A Phase 3 study of Metastatic Clear Cell Renal Cell Carcinoma and Advanced Clear Cell Renal Cell Carcinoma, sponsored by Arcus Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
- 20
- Study locations
NCT07011719: Recruiting Phase 3 study of Metastatic Clear Cell Renal Cell Carcinoma and Advanced Clear Cell Renal Cell Carcinoma, sponsored by Arcus Biosciences.
NCT07011719 is a Phase 3 study of Metastatic Clear Cell Renal Cell Carcinoma and Advanced Clear Cell Renal Cell Carcinoma that is actively recruiting participants, run by Arcus Biosciences. The registered enrollment target is 720 participants, above the 98-participant average among 13 other Metastatic Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (635% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07011719, a Phase 3 study of Metastatic Clear Cell Renal Cell Carcinoma and Advanced Clear Cell Renal Cell Carcinoma, is actively recruiting participants, sponsored by Arcus Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabozantinib
- DRUG Casdatifan
Study Locations (20)
California
- City Of Hope National Medical Center - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- UCLA Hematology Oncology - 100 Med Plaza - Los Angeles
- University of California San Diego Moores Cancer Center - San Diego
Georgia
- Piedmont Cancer Institute OneOncology - Atlanta
- Emory University - Atlanta - Atlanta
- City of Hope Cancer Center Atlanta - Newnan
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Ohio
- Cleveland Clinic Foundation - Cleveland
- University Hospitals Cleveland Medical Center - Cleveland
Arizona
- City of Hope - Phoenix Cancer Center - Goodyear
Connecticut
- Yale University - New Haven
Illinois
- City of Hope - Chicago Cancer Center - Zion
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
What NCT07011719 shows while recruiting
NCT07011719 is an interventional study that assigns participants to a tested intervention. The registered 720 participants enrollment target is mid-sized for trials with a published cap, above the 98-participant average among 13 other Metastatic Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (635% higher).
The record links to 2 conditions, with Metastatic Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07011719 names 20 study sites across 13 states, led by California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07011719 about?
NCT07011719 is a clinical study titled "Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma". The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti...
What is the current status of trial NCT07011719?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2025-09-08. Estimated completion is 2030-12.
What conditions does trial NCT07011719 study?
This clinical trial studies the following conditions: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT07011719?
The interventions under investigation include: Placebo (DRUG), Cabozantinib (DRUG), Casdatifan (DRUG).
Who is sponsoring clinical trial NCT07011719?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011719 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07011719's enrollment target sits among peer trials
720 1st of 13 higher than 13 of 13 other Metastatic Clear Cell Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RECRUITING · Phase 3
-
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RECRUITING
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RECRUITING · Phase 1
-
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
RECRUITING · Phase 1
-
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
- NCT05466214 · 720 participants · NA
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI